• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Anatomopathological findings correlated with high-dose recombinant interleukin-2. Review of the literature and description of 2 autopsy cases].

作者信息

Canzonieri V, Monfardini S, Carbone A

机构信息

Divisioni di Anatomia Patologica e di Oncologia Medica, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico.

出版信息

Pathologica. 1992 Jul-Aug;84(1092):473-81.

PMID:1491889
Abstract

After review of the pertinent literature on pathologic findings associated with Interleukin-2 (IL-2) therapy for metastatic malignancies (melanomas, renal cell carcinomas), two autoptic cases are described with particular emphasis on the cardiovascular and pulmonary changes. The authors report on the occurrence of massive transmural acute myocardial infarct in a patient with metastatic cutaneous melanoma, treated with recombinant IL-2, who did not show atherosclerotic lesions of the coronary arteries. Conversely, myocardial lesions were not found in the other patient with metastatic renal cell carcinoma, treated with recombinant IL-2; he had severe generalized atherosclerosis and died of pulmonary causes. It is suggested that myocardial direct toxic effects of IL-2 associated with capillary leak syndrome may determine a myocardial infarct. It is concluded that IL-2 therapy is not contra-indicated in oncologic patients with atherosclerosis of the coronaries if they are carefully monitored.

摘要

相似文献

1
[Anatomopathological findings correlated with high-dose recombinant interleukin-2. Review of the literature and description of 2 autopsy cases].
Pathologica. 1992 Jul-Aug;84(1092):473-81.
2
Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.白细胞介素-2(IL2)用于转移性肾细胞癌和黑色素瘤的两项连续II期研究结果:大剂量持续静脉输注IL2以及皮下注射IL2联合α干扰素。
Rev Med Univ Navarra. 1996 Jul-Sep;40(3):6-12.
3
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.使用大剂量推注白细胞介素-2治疗283例连续性转移性黑色素瘤或肾细胞癌患者。
JAMA. 1994;271(12):907-13.
4
Vascular leak syndrome associated with interleukin-2: chest radiographic manifestations.与白细胞介素-2相关的血管渗漏综合征:胸部X线表现
Radiology. 1990 Jul;176(1):191-4. doi: 10.1148/radiology.176.1.2353090.
5
Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.黑色素瘤患者中的白癜风:正常组织抗原可成为癌症免疫治疗的靶点。
J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):81-4.
6
The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma.白细胞介素-2对转移性黑色素瘤和肾细胞癌患者的血液学毒性。
Cancer. 1995 Feb 15;75(4):1030-7. doi: 10.1002/1097-0142(19950215)75:4<1030::aid-cncr2820750420>3.0.co;2-5.
7
A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma.一项针对晚期肾细胞癌患者,采用分泌白细胞介素-2的异体人白细胞抗原A2匹配肾癌细胞进行免疫治疗的初步研究。
Hum Gene Ther. 1992 Dec;3(6):691-703. doi: 10.1089/hum.1992.3.6-691.
8
Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.高剂量白细胞介素-2联合可溶性p75肿瘤坏死因子受体免疫球蛋白G嵌合体治疗晚期黑色素瘤和肾细胞癌患者的随机安慰剂对照临床试验。
J Clin Oncol. 1997 Mar;15(3):1052-62. doi: 10.1200/JCO.1997.15.3.1052.
9
Anti-tumor effects of interleukin 2 against renal cell carcinoma. In vitro study and clinical application.白细胞介素2对肾细胞癌的抗肿瘤作用。体外研究与临床应用。
Prog Clin Biol Res. 1990;350:263-73.
10
Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.199例转移性黑色素瘤或肾癌患者使用大剂量白细胞介素-2后出现的肾功能障碍。
J Clin Oncol. 1994 Dec;12(12):2714-22. doi: 10.1200/JCO.1994.12.12.2714.